Advertisement
Advertisement
U.S. Markets open in 48 mins
Advertisement
Advertisement
Advertisement
Advertisement

IBEX Technologies Inc. (IBXNF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.38690.0000 (0.00%)
At close: 11:17AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.3869
Open0.3869
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.3869 - 0.3869
52 Week Range0.0011 - 0.4600
Volume3,500
Avg. Volume7,943
Market Cap9.604M
Beta (5Y Monthly)0.42
PE Ratio (TTM)10.18
EPS (TTM)0.0380
Earnings DateMar 15, 2022 - Mar 21, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    IBEX Technologies Announces Normal Course Issuer Bid

    MONTREAL, Aug. 02, 2022 (GLOBE NEWSWIRE) -- IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today announced that the TSX Venture Exchange (“TSXV”) has approved IBEX’s normal course issuer bid (“NCIB”). Under the NCIB, IBEX may purchase for cancellation a maximum of 1,800,000 common shares, representing approximately 9.9% of the 18,198,067 shares forming IBEX’s public float. The shares may be purchased through the facilities of the TSXV. The NCIB will commence on August 5, 202

  • Simply Wall St.

    Are IBEX Technologies Inc.'s (CVE:IBT) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

    With its stock down 31% over the past three months, it is easy to disregard IBEX Technologies (CVE:IBT). But if you pay...

  • GlobeNewswire

    IBEX Reports Results for the Third Quarter and the Nine Months Ended April 30, 2022

    MONTRÉAL, Québec, June 10, 2022 (GLOBE NEWSWIRE) -- IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today reported its financial results for the nine months ended April 30, 2022. “We are pleased with the continued growth in sales, driven by strong sales of heparinase-based products, as well as by the sales of aryl-acyl amidase, a product used in tests for acetaminophen poisoning; and also with the continued strengthening of the Company’s balance sheet” said Paul Baehr, IBEX P

Advertisement
Advertisement